Evolutionary Genomics, Inc.
Evolutionary Genomics, Inc.
Your view on FNAM
Overview
What the company does, where it operates, and who runs it.
About Evolutionary Genomics, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Steve Warnecke
- Headquarters
- 1026 Anaconda Drive, Castle Rock, CO, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Steve Warnecke
- Headquarters
- 1026 Anaconda Drive, Castle Rock, CO, US
Evolutionary Genomics, Inc., together with its subsidiaries, engages in the research and identification of positively selected genes in humans, animals, and commercial crops.
The company develops Adapted Traits Platform, a technology platform to identify genes for enhancing crop plant traits, such as yield, sugar content, biomass, drought tolerance, and pest/disease resistance. It serves governmental organizations, non-profit foundations, and commercial entities.
Evolutionary Genomics, Inc. was incorporated in 1990 and is based in Castle Rock, Colorado.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Evolutionary Genomics, Inc., and the rating behind it. FNAM last traded at $0.0002; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Evolutionary Genomics, Inc.. Starting points for Evolutionary Genomics, Inc.: EPS -$0.30, beta -0.16 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Evolutionary Genomics, Inc.. Evolutionary Genomics, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Evolutionary Genomics, Inc.. Trailing twelve-month EPS for Evolutionary Genomics, Inc. stands at -$0.30. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Evolutionary Genomics, Inc.. Evolutionary Genomics, Inc. has reported as a listed company since 2012. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Evolutionary Genomics, Inc. valued side by side against its closest peers. Evolutionary Genomics, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Evolutionary Genomics, Inc., and how their positions are changing. At a $1,331 market value, institutional positions materially move Evolutionary Genomics, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Evolutionary Genomics, Inc. executives and directors. Shares of Evolutionary Genomics, Inc. have traded between $0.0002 and $0.45 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Evolutionary Genomics, Inc.. Evolutionary Genomics, Inc. is a $1,331 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Evolutionary Genomics, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Evolutionary Genomics, Inc.. Coverage tracks Evolutionary Genomics, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.